Recent studies have shown exceptional responses to neoadjuvant immunotherapy with botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1) for pMMR/MSS colorectal cancer, suggesting another approach to improve tumor regression and restore the TiME [36]. The gene discussed is CTLA4; the disease is colorectal cancer.